{"tema_id":"6900","string":"Eschscholzia californica Cham.","created":"2010-10-22 11:19:07","code":null,"modified":"2010-10-22 11:19:45","notes":[{"@type":"Nota de alcance","@lang":"es","@value":"\n\n\n\n\n\n\n\nPARTE UTILIZADA= Used part: Las flores.\u00a0\nACCI\u00d3N FARMACOL\u00d3GICA= Pharmacological action: Sedante, ansiolitico y antiespasm\u00f3dico. \n\n\n\n\n\nPOSOLOG\u00cdA= Posology: Infusi\u00f3n : 2 g de droga por 150 ml de agua. Tres o mas tazas al d\u00eda. Extracto fluido (1:1): 30-50 gotas (1-2 ml), una tres veces al d\u00eda.\u00a0\n\n\n\n\nCOMPOSICI\u00d3N QU\u00cdMICA= Chemical composition: Toda la planta tiene una mezcla compleja de alcaloides cuya composici\u00f3n var\u00eda dependiendo de cada \u00f3rgano. La parte a\u00e8rea contiene entre\u00a0 0,29 y 0,56 % de alcaloides de los cuales el principal es la californidina , una base cuaternaria de tipo pav\u00ednico; tambi\u00e9n destaca la escolicidina , base terciaria an\u00e1loga de la anterior, y laurascolcina, de tipo aporf\u00ednico. otros alcaloides en menor proporci\u00f3n son : protopina, sanguinaria , celeritina y alocriptopina.\u00a0"},{"@type":"Nota de alcance","@lang":"es","@value":"DIVERSIDAD GEN\u00c9TICA Y MEJORAMIENTO DE PLANTAS MEDICINALES= Medicinal plants and improvement of medicinal herbs: \n\nFLORICAULA\/LEAFY-like genes were initially characterized as flower meristem identity genes.\u00a0 In a range of angiosperms, expression occurs also in vegetative shoot apices and developing leaves, and in some species with dissected leaves expression is perpetuated during organogenesis at the leaf marginal blastozone.\u00a0 The evolution of these expression patterns and assocd. functions is not well understood.\u00a0 We have isolated and characterized aFLORICAULA-like gene from California Poppy, Eschscholzia californica Cham. (Papaveraceae), a species belonging to the basal eudicot clade Ranunculales. EcFLO encodes a putative 416-amino-acid protein with highest similarity to homologous genes from Trochodendron and Platanus.\u00a0 We show that EcFLO mRNA is expressed during the vegetative phase of the shoot apical meristem and in developing dissected leaves in a characteristic manner.\u00a0 This pattern is compared to that of other eudicots and discussed in terms of evolution of FLORICAULA expression and function."},{"@type":"Nota de alcance","@lang":"es","@value":"\u00daLTIMOS AVANCES EN LA QU\u00cdMICA Y ACTIVIDADES BACTERIOL\u00d3GICAS EN LAS PLANTAS MEDICINALES= Medicinal plants, last advances on chemistry and bacteria activities on the medicinal herbs\n\nThe isoquinoline alkaloids hunnemanine and norsanguinarine have been isolated from methanolic extract of the whole plant of Eschscholzia californica.\u00a0 These two alkaloids were checked for their antifungal activity against phytopathogenic fungi Alternaria melongenae, A. brassicola, A. brassicae, Curvularia lunata, C. maculans, Helminthosporium pennisetti, H. oryzae, H. turcicum, Fusarium undum and F. lini.\u00a0 Hunnemanine exhibited 100 % inhibition of spore germination of A. brassicae, H. pennisetti and F. lini at 1000 ppm whereas norsanguinarine exhibited 100 % inhibition of A. brassicicola and C. maculans at this concentration."},{"@type":"Nota de alcance","@lang":"es","@value":"Patente extra\u00edda del Chemical Abstracts= Patent extrated from the Database Chemical Abstracts\n\u00a0\nMethods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications.\u00a0\u00a0\u00a0\u00a0\u00a0 Crain, Steven; Crain, William E.; Crain, Stanley M.; Crain, Michael.\u00a0 (Pondera Biotechnologies, LLC, USA).\u00a0\u00a0\u00a0 U.S. Pat. Appl. Publ.\u00a0 (2011),\u00a0\u00a0\u00a0\u00a0 74pp.\u00a0 CODEN: USXXCO\u00a0 US\u00a0 20110159048\u00a0 A1\u00a0 20110630\u00a0 Patent\u00a0 written in English.\u00a0\u00a0\u00a0 Application: US\u00a0 2010-973839\u00a0 20101220.\u00a0 Priority: US\u00a0 2009-289293P\u00a0 20091222; US\u00a0 2010-309766P\u00a0 20100302; US\u00a0 2010-322665P\u00a0 20100409; US\u00a0 2010-323465P\u00a0 20100413; US\u00a0 2010-330631P\u00a0 20100503; US\u00a0 2010-351653P\u00a0 20100604; US\u00a0 2010-375463P\u00a0 20100820; US\u00a0 2010-385873P\u00a0 20100923; US\u00a0 2010-386952P\u00a0 20100927.\u00a0 CAN 155:144481\u00a0\u00a0\u00a0 AN 2011:823609\u00a0\u00a0\u00a0 CAPLUS\u00a0\u00a0 (Copyright (C) 2011 ACS on SciFinder (R))\u00a0\u00a0 \n\nThe present invention relates to methods and compns. for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone.\u00a0 Distress Dysfunction refers to the experience of dysfunctional emotional and phys. distress that interferes with the individual's quality of life and functioning.\u00a0 A novel understanding of the bimodal opioid modulation of pain, and its impact, through serotonergic, dopaminergic, epinephrinergic, and norepinephrinergic processes, on hedonic tone, leads directly to new generation pharmaceutical formulations that are remarkably safe and effective for the treatment of a wide variety of Distress Dysfunctions, including anxiety, depression, anger, insomnia, mood disorders, eating disorders, sexual problems, pain, substance and behavioral addictions, gastrointestinal disorders, autistic spectrum disorders, attention-deficit and hyperactivity disorders, and other emotional and phys. distress disorders.\u00a0 The foundation of this discovery is the power of Receptor Switchers, such as ultra-low-dose and very-low-dose opioid antagonists and GM1 ganglioside attenuators, in blocking acute and protracted excitatory opioid receptor signaling.\u00a0 Co-administration of Receptor Switchers with Endorphin Enhancers, such as specific cAMP PDE inhibitors and excitatory amino acids, is an excellent formulation for restoring healthy homeostatic balance to the endogenous opioid system, using the body's endorphins to reduce emotional and phys. distress, and through synergistic and homeostatic processes, restoring pos. hedonic tone.\u00a0 The addn. of Synergistic Enhancers, such as amino acids, SSRI and SNRI agents, and non-opioid analgesics, as well as Exogenous Opioids, enhances and prolongs these therapeutic benefits.\n\u00a0The novel principles discovered by this invention also teach a new generation of safe and effective formulations for the treatment of respiratory conditions, neuropathy, and nociceptive pain.\u00a0 The combination of a Receptor Switcher, such as ultra-low-dose naltrexone, very-low-dose naltrexone, methylmethane, NAC, or magnesium sulfate, with an Endorphin Enhancer, such as ginkgo biloba, guarana, roflumilast, caffeine, or theophylline, simultaneously blocked protracted excitatory opioid signaling and increased endorphin levels, thereby reducing emotional and phys. distress and enhancing a sense of well-being.\u00a0 A lotion was created by combining a penetrating skin cream with powd. loperamide (ten 2 mg tablets) and methylmethane (2 g).\u00a0 Four subjects with moderate-to-severe chronic arthritic joint pain applied the lotion to the painful areas of their body, up to 4 times daily, over a period of one week.\u00a0 All subjects reported at least a moderate improvement in joint pain with no side effects.\n\n"},{"@type":"Nota bibliogr\u00e1fica","@lang":"es","@value":"\n\n\n\n1) Fitoterapia : vademecum de prescripci\u00f3n.\u00a0 4\u00aa\u00a0 ed.\u00a0 Barcelona : Masson, 2003, p.119.\n\n2) BUSCH, Andrea; GLEISSBERG, Stefan. EcFLO, aFLORICAULA-like gene from Eschscholzia californica is expressed during organogenesis at the vegetative shoot apex.\u00a0 Planta. 2003, vol.217, n\u00ba6, p.841-848. \n\u00a0\n3) SINGH, S., et al. Antifungal activity of the alkaloids from Eschscholzia californica. Folia microbiologica. 2009, vol.54, n\u00ba3, p.204-206. "}]}